On Monday, Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) was 12.79% up from the session before settling in for the closing price of $0.51. A 52-week range for LXRX has been $0.28 – $2.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 600.60%. When this article was written, the company’s average yearly earnings per share was at 42.06%. With a float of $179.54 million, this company’s outstanding shares have now reached $361.49 million.
Let’s determine the extent of company efficiency that accounts for 103 employees. In terms of profitability, gross margin is 97.55%, operating margin of -634.2%, and the pretax margin is -644.78%.
Lexicon Pharmaceuticals Inc (LXRX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Lexicon Pharmaceuticals Inc stocks. The insider ownership of Lexicon Pharmaceuticals Inc is 50.33%, while institutional ownership is 34.87%. The most recent insider transaction that took place on Aug 15 ’24, was worth 480,000.
Lexicon Pharmaceuticals Inc (LXRX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.06% per share during the next fiscal year.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Trading Performance Indicators
You can see what Lexicon Pharmaceuticals Inc (LXRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.44. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.64, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.28 in one year’s time.
Technical Analysis of Lexicon Pharmaceuticals Inc (LXRX)
Looking closely at Lexicon Pharmaceuticals Inc (NASDAQ: LXRX), its last 5-days average volume was 6.1 million, which is a drop from its year-to-date volume of 13.64 million. As of the previous 9 days, the stock’s Stochastic %D was 69.88%. Additionally, its Average True Range was 0.08.
During the past 100 days, Lexicon Pharmaceuticals Inc’s (LXRX) raw stochastic average was set at 36.42%, which indicates a significant decrease from 90.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 124.99% in the past 14 days, which was lower than the 195.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5099, while its 200-day Moving Average is $1.1653. However, in the short run, Lexicon Pharmaceuticals Inc’s stock first resistance to watch stands at $0.6160. Second resistance stands at $0.6569. The third major resistance level sits at $0.7189. If the price goes on to break the first support level at $0.5131, it is likely to go to the next support level at $0.4511. Should the price break the second support level, the third support level stands at $0.4102.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Key Stats
There are 246,237K outstanding shares of the company, which has a market capitalization of 207.86 million. As of now, sales total 31,080 K while income totals -200,400 K. Its latest quarter income was 26,550 K while its last quarter net income were -33,770 K.
